NCT05823714View on ClinicalTrials.gov

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2026

Conditions
Allogeneic Hematopoietic Stem Cell TransplantationAcute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

VEN+AZA+Modified BUCY

"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER